Skip to main content

Remote Job Finders (RJF)

Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision

The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.

7 biopharma M&A deals where layoffs followed

Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired by Gilead Sciences and Novartis, respectively.
Scroll to top